FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Pharmacy Compounding Panel Renewed

Federal Register notice: FDA renews its Pharmacy Compounding Advisory Committee for an additional two years.

latest-news-card-1
Federal Register

23 No-Longer-Marketed ANDAs Withdrawn

Federal Register notice: FDA withdraws approval of 23 ANDAs from multiple applicants after they notified the agency that the products are no longer be...

latest-news-card-1
Human Drugs

AstraZeneca Reports Favorable Calquence Data

AstraZeneca says data from its Phase 3 AMPLIFY trial showed that Calquence (acalabrutinib) in combination with venetoclax showed favorable progression...

latest-news-card-1
Human Drugs

Kaleo Social Media Post Runs Afoul of FDA

FDA cites a Kaleo social media post about Auvi-Q (epinephrine injection) because it presented benefit information but failed to include any risk infor...

latest-news-card-1
Human Drugs

Carie Boyd Pharma Hit with FDA-483

FDA issues Carie Boyd Pharmaceuticals a six-observation Form FDA-483 after inspecting the firms Irving,TX outsourcing facility last month.

latest-news-card-1
Human Drugs

Alpha Cognitions Zunveyl OKd for Alzheimers

FDA approves an Alpha Cognition NDA for ZUNVEYL (benzgalantamine) for treating mild-to-moderate Alzheimers disease.

latest-news-card-1
Medical Devices

Elixir Med. Breakthrough Status for Bioadaptive Implant

FDA grants Elixir Medical a breakthrough device designation for its DynamX Sirolimus-Eluting Coronary Bioadaptor System for use in treating coronary a...

latest-news-card-1
Human Drugs

Brassica Pharma Hit with 10-item FDA-483

A January inspection of Brassica Pharmas Indian sterile drug manufacturing facility leads to a 10-observation Form FDA-483 that cites significant GMP ...

latest-news-card-1
Human Drugs

Suns JAK Inhibitor OKd for Alopecia Areata

FDA approves a Sun Pharmaceutical Industries NDA for Leqselvi (deuruxolitinib) 8 mg tablets for treating adults with severe alopecia areata.

latest-news-card-1
Federal Register

Pulmonary-Allergy Drugs Panel Renewal

Federal Register notice: FDA announces the renewal for two years of its Pulmonary-Allergy Drugs Advisory Committee.